Simuni T, on behalf of the Parkinson Study Group. A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results. AAN 2019.
Effect van evobrutinib op ‘slowly expanding lesion’-volume bij relapsing MS
apr 2024 | Multipele Sclerose